Sorrento Therapeutics, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Sorrento Therapeutics, Inc. Sorrento Therapeutics, Inc. (SRNE) is a clinical-stage biopharmaceutical company that develops next-generation therapies targeting cancer, infectious diseases, autoimmune and inflammatory conditions, metabolic disorders, and non-opioid pain management; its core offerings include proprietary antibody technologies such as fully human antibody libraries via platforms like G-MAB, SO-MAB, and TOS-BAT for bispecific antibodies and antibody-drug conjugates, chimeric antigen receptor T-cell (CAR-T) and dimeric antigen receptor T-cell (DAR-T) therapies, oncolytic viruses, IL-2 immune modulators, resiniferatoxin (RTX) as a TRPV1 agonist neurotoxin for severe cancer and osteoarthritis pain, and antiviral candidates like STI-1558 and COVI-MSC for coronaviruses; through its former majority-owned subsidiary Scilex Holding Company, it previously commercialized non-opioid pain products including ZTlido (lidocaine topical system 1.8% for postherpetic neuralgia), ELYXYB (oral solution for acute migraine), and Gloperba (liquid colchicine for gout flare prophylaxis), alongside pipeline assets like SP-102 (SEMDEXA, dexamethasone gel for sciatica), SP-103 (lidocaine system for neck and back pain), and SP-104 (low-dose naltrexone for fibromyalgia). Sorrento Therapeutics, Inc. operates primarily in the United States with global research and development efforts, including facilities in San Diego, California, its headquarters location since its founding in 2006 (with operations tracing to 1989 precursor activities); the company serves pharmaceutical partners, healthcare providers, and patients across oncology, immunology, virology, and pain sectors, leveraging subsidiaries like Scilex for commercial-stage non-opioid solutions and earlier acquisitions such as ACEA Therapeutics in 2021 for small-molecule kinase inhibitors like abivertinib (targeting NSCLC and lymphomas) and AC0058 (BTK inhibitor for lupus and autoimmune diseases), plus a cGMP facility in China. Recent major developments include filing for Chapter 11 bankruptcy protection in February 2023 in the U.S. Bankruptcy Court for the Southern District of Texas to safeguard operations amid liquidity challenges and litigation judgments exceeding $173 million from licensing disputes with entities like NantCell, NANTibody, and NantPharma (the latter resulting in a $125 million arbitration award confirmation in favor of Sorrento); securing interim court approval for $75 million debtor-in-possession financing from JMB Capital Partners in February 2023 and consummating a sale of substantially all its Scilex Holding Company equity (common shares, preferred shares, and warrants) in September 2023 for approximately $105 million to address debts and support reorganization; pursuing strategic alliances such as a 2015 $150 million investment led by Ally Bridge Group for global expansion and earlier merger pursuits involving subsidiaries like Scilex with Vickers Vantage Corp. I (announced 2022, pro forma value $1.64 billion) and Semnur Pharmaceuticals with Denali Capital Acquisition Corp. (agreement August 2024, $2.5 billion pre-transaction value, targeting Q1 2025 close under Nasdaq ticker SMNR).
Sorrento Voyage Announces Expanded Luxury Boat Tours and Proposal Experiences Along the Amalfi Coast
Sorrento Therapeutics (NASDAQ:SRNE) and Cortexyme (NASDAQ:CRTX) Head to Head Analysis
Sorrento Therapeutics (NASDAQ:SRNE) versus NKGen Biotech (NYSE:NKGN) Head-To-Head Review
Analyzing Sorrento Therapeutics (SRNEQ) and Its Competitors
Financial Survey: Sorrento Therapeutics (SRNEQ) and Its Rivals
DSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel Infills
Sorrento Resources Announces Appointment of Alex Bugden as President and Chief Executive Officer
Sorrento Resources to Sell Three Newfoundland Properties to Gold Hunter
Sorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified Person
DSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh Railing
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
Sorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid
Scilex: Sorrento's Better Half, Or Its Entangled, Erratic Mover?
Gold Hunter Resources Completes the Sale of Certain Properties to Sorrento Resources
Gold Hunter Resources Inc. Sells a Portion of Its Newfoundland Projects to Sorrento Resources
Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the ASCO 2023 Meeting
Why Sorrento Therapeutics Stock Crashed Today
The $75 Million Reason Sorrento (SRNE) Stock Is Moving Today
Penny Stocks To Buy? 7 To Watch Now After Big News
How to Stay Disciplined When Investing in Penny Stocks